Biotech CEO Reviews the Efficacy of Ketamine, MDMA & Psychedelic Therapy for Mental Health

Episode Description below⬇️ Leave an iTunes review here - https://apple.co/3i60XWu Subscribe on Youtube here - https://bit.ly/3o1M4Z3 Follow us on your favorite podcast platform here - https://bit.ly/3kTfNkY Find out more about our sponsor Publicize here - https://bit.ly/3BqDUxc According to The NewYorker, ketamine therapy is going mainstream, as the drug has been shown to help people suffering from anxiety and depression. Moreover, evidence that this drug can help those suffering from mental health issues has been very promising, as stated in the National Library of Medicine, with results showing a significant improvement in depression, anxiety, and the severity of illness after ketamine treatment. But here at Brains Byte Back we want to understand how this drug is being used and how it stands so to impact the future of treating mental illnesses, so we spoke with Dr. Tiago Marques, CEO at Pasithea Therapeutics, a biotech company at the forefront of research solutions to the world’s mental health problems. In today’s episode, Marques tell us how Pasithea first started, and shares some insights into day-to-day research at the company. He also explains how mobile clinics and controlled ketamine infusion work. Alongside, how effective is ketamine for treating PTSD, depression, and other similar issues. And finally Marques shares some interesting trends in the medical space using psychedelics, and explains what are the legal implications of working in the psychedelic space in the US right now.

There are no comments yet.

Please log in to write the first comment.